arrow
M

Miriam Grazia Ferrara

thermo fisher scientific
H指数:15
被引数:927

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance

PI3K/mTORC2-RICTOR轴在早期鳞状非小细胞肺癌中的研究:基因组学、分子表达及其临床相关性

2025-11-070
OA
Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI plus CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)

评估免疫检查点抑制剂联合化疗(ICI plus CT)在早期非小细胞肺癌(NSCLC)临床试验中的不确定性和脆弱性,采用信息性删失和生存推断脆弱性指数(SIFI)进行分析。

2024-09-010
PRE
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer

解开有丝分裂纺锤体: 肺癌中的极光激酶抑制剂的重点

2022-10-279
OAAI
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
2022-01-215
OAAI
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

针对晚期非小细胞肺癌的KRAS复兴: 旧失败后的新机遇

2021-12-232
OAAI
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

PTEN丢失是接受酪氨酸激酶抑制剂的EGFR突变晚期非小细胞肺癌患者肿瘤异质性和不良预后的预测指标

2021-07-0114
PRE
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

基于药物的评分对接受一线免疫治疗的晚期非小细胞肺癌患者的预测能力

2021-06-0124
OAAI
Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

在一项大型多中心真实世界研究中接受一线单药pembrolizumab治疗的PD-L1表达> 50% 的NSCLC患者的进展后结局

2021-05-0120
OAAI
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

抗生素治疗和其他药物对一线pembrolizumab与细胞毒性化疗治疗的非小细胞肺癌患者肿瘤学结局的差异影响

2021-04-0797
OAAI
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

在PD-L1表达 ≥ 50% 的NSCLC患者的大型真实队列中,派姆单抗的免疫相关不良事件及其与临床结局的关系

2020-11-0163
OAAI